Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel M Witt

Showing results (31-40 of 167) with videos related to

Pageof 17
Sort By:
Chest|May 15, 2007
Warfarin and antiplatelet combination use among commercially insured patients enrolled in an anticoagulation management serviceSamuel G Johnson, Daniel M Witt, Todd R Eddy, et al.
Thrombosis Research|March 26, 2013
Thromboembolic and bleeding outcomes of low-intensity warfarin thromboprophylaxis following elective total hip arthroplastyNathan P Clark, Stephanie E Cho, Thomas Delate, et al.
Journal of Thrombosis and Thrombolysis|February 23, 2020
The role of clinical pharmacy anticoagulation services in direct oral anticoagulant monitoringAubrey E Jones, Jordan B King, Kibum Kim, et al.
Pharmacotherapy|March 26, 2010
Unfractionated heparin dose requirements targeting intermediate intensity antifactor Xa concentration during pregnancyNathan P Clark, Thomas Delate, Steven J Cleary, et al.
Thrombosis Research|March 14, 2025
Who are we bridging? Description of warfarin patients receiving injectable bridging therapySara R Vazquez, Connor Jensen, Aaron S Wilson, et al.
Thrombosis Journal|October 16, 2021
Replacement of traditional prothrombin time monitoring with the new Fiix prothrombin time increases the efficacy of warfarin without increasing bleeding. A review articlePall T Onundarson, Ragnar Palsson, Daniel M Witt, et al.
Journal of Thrombosis and Thrombolysis|March 14, 2008
A descriptive evaluation of warfarin use in patients receiving hospice or palliative care servicesRobin R Hill, Kerri D Martinez, Thomas Delate, et al.
Thrombosis Research|August 25, 2009
Analysis of unfractionated heparin dose requirements to target therapeutic anti-Xa intensity during pregnancyNathan P Clark, Thomas Delate, Steven J Cleary, et al.
Pharmacotherapy|June 8, 2013
Assessment of warfarin dosing requirements after bariatric surgery in patients requiring long-term warfarin therapyAdriane N Irwin, Kathleen H McCool, Thomas Delate, et al.
Journal of Thrombosis and Thrombolysis|July 19, 2019
Description of anti-Xa monitoring practices during low molecular weight heparin useAlbert Lin, Sara R Vazquez, Aubrey E Jones, et al.
Pageof 17

Showing results (31-40 of 167) with videos related to

Sort By:
Pageof 17
Chest|May 15, 2007
Warfarin and antiplatelet combination use among commercially insured patients enrolled in an anticoagulation management serviceSamuel G Johnson, Daniel M Witt, Todd R Eddy, et al.
Thrombosis Research|March 26, 2013
Thromboembolic and bleeding outcomes of low-intensity warfarin thromboprophylaxis following elective total hip arthroplastyNathan P Clark, Stephanie E Cho, Thomas Delate, et al.
Journal of Thrombosis and Thrombolysis|February 23, 2020
The role of clinical pharmacy anticoagulation services in direct oral anticoagulant monitoringAubrey E Jones, Jordan B King, Kibum Kim, et al.
Pharmacotherapy|March 26, 2010
Unfractionated heparin dose requirements targeting intermediate intensity antifactor Xa concentration during pregnancyNathan P Clark, Thomas Delate, Steven J Cleary, et al.
Thrombosis Research|March 14, 2025
Who are we bridging? Description of warfarin patients receiving injectable bridging therapySara R Vazquez, Connor Jensen, Aaron S Wilson, et al.
Thrombosis Journal|October 16, 2021
Replacement of traditional prothrombin time monitoring with the new Fiix prothrombin time increases the efficacy of warfarin without increasing bleeding. A review articlePall T Onundarson, Ragnar Palsson, Daniel M Witt, et al.
Journal of Thrombosis and Thrombolysis|March 14, 2008
A descriptive evaluation of warfarin use in patients receiving hospice or palliative care servicesRobin R Hill, Kerri D Martinez, Thomas Delate, et al.
Thrombosis Research|August 25, 2009
Analysis of unfractionated heparin dose requirements to target therapeutic anti-Xa intensity during pregnancyNathan P Clark, Thomas Delate, Steven J Cleary, et al.
Pharmacotherapy|June 8, 2013
Assessment of warfarin dosing requirements after bariatric surgery in patients requiring long-term warfarin therapyAdriane N Irwin, Kathleen H McCool, Thomas Delate, et al.
Journal of Thrombosis and Thrombolysis|July 19, 2019
Description of anti-Xa monitoring practices during low molecular weight heparin useAlbert Lin, Sara R Vazquez, Aubrey E Jones, et al.
Pageof 17